Usefulness of the d-ROMs test for prediction of cardiovascular events

Pre‐diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta‐analysis of two large population‐based studies

“…Although high d‐ROM levels were identified as an independent risk factor for LC, CRC and BC incidence, this has little clinical implications for cancer prevention because we showed that a d‐ROM test result cannot improve prediction of these cancer sites if added to a model of established risk factors. However, the d‐ROM test may be measured by general practitioners as a general marker of health and as an indicator for an increased risk for not only specific cancer sites but also cardiovascular diseases, chronic kidney disease and premature death . If the d‐ROM test was conducted in this context, it may be used to motivate individuals with increased serum d‐ROM levels >340 Carr U (threshold for increased all‐cause mortality) to change their lifestyle.…”

“…However, the d-ROM test may be measured by general practitioners as a general marker of health and as an indicator for an increased risk for not only specific cancer sites but also cardiovascular diseases, 9,[33][34][35] chronic kidney disease 36 and premature death. 7,9 If the d-ROM test was conducted in this context, it may be used to motivate individuals with increased serum d-ROM levels >340 Carr U (threshold for increased all-cause mortality) 9 to change their lifestyle.…”

Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia

“…Based on our previous experience, in order to evaluate the OS we chose d‐ROMs test and BAP test as suitable tests to measure total oxidant and total antioxidant capacity, respectively, on blood serum samples . This choice was dictated by the well‐established analytical performances of these tests that allow them (i) to accurately measure the OS level ex vivo either in subject at risk for OS (eg cigarette smokers and alcohol drinkers) or in patients suffering from OS‐related diseases, including cardiovascular and inflammatory diseases, cancer and onco‐haematological disorders; (ii) to be sensitive to changes occurring after specific treatments, antioxidant supplementation and radio‐ or chemotherapy; (iii) to anticipate the progression of OS‐related diseases during a systematic monitoring; and (iv) to be minimally invasive, highly compliant, fast, with an optimal cost/benefit ratio . Both d‐ROMs test and BAP test have been validated by the gold standard methods to assess redox balance ex vivo (ie the electron spin magnetic resonance spectrometry), and their reference values in large cohorts of general population are well established .…”

Decreased arginine bioavailability in patients with coronary artery disease in an outpatient setting

“…Blood serum was obtained by centrifugation of the samples at 3,000 rpm for 10 min at 4°C and aliquots of serum were stored at -80°C until analysis. A reactive oxygen metabolites (d-ROMs) test was used to measure serum hydroperoxides as an index of oxidative stress as described previously 18) . Serum L-arginine, Lcitrulline, L-ornithine, asymmetric dimethyl-arginine (ADMA), and symmetric dimethyl-arginine were measured by high-performance liquid chromatography using an RF-20 A fluorescence detector (Shimadzu Corp., Kyoto, Japan) with a Symmetry C18 column (3.9 × 150 mm, 5 μm particle size; Waters Corp., Milford, MA USA).…”